Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)

NCT02891226 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02891226
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02891226 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Parallel-Arm, Placebo-Controlled Study of LY3074828 in Subjects With Active Crohn's Disease (SERENITY)
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
December 14, 2016
Completion date
February 5, 2021
Enrollment
191 (actual)
Sites
108

Conditions

As the registry lists them; a condition with its own page is linked.

crohn's disease